These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 33691383)

  • 1. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
    Fiorcari S; Atene CG; Maffei R; Debbia G; Potenza L; Luppi M; Marasca R
    Haematologica; 2021 Aug; 106(8):2265-2268. PubMed ID: 33691383
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 4. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
    Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
    [No Abstract]   [Full Text] [Related]  

  • 5. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM
    Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
    Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT
    Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Molica S; Allsup DJ; Polliack A
    Leuk Lymphoma; 2022 Aug; 63(8):1771-1773. PubMed ID: 35703117
    [No Abstract]   [Full Text] [Related]  

  • 10. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
    Khan S; Durairaj S; Phumphukhieo P; Holding S; Allsup D
    Leuk Lymphoma; 2021 Jul; 62(7):1786-1789. PubMed ID: 33596758
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
    Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    Molica S; Giannarelli D; Visentin A; Reda G; Sportoletti P; Frustaci AM; Chiarenza A; Ciolli S; Vitale C; Laurenti L; De Paoli L; Murru R; Gentile M; Moia R; Rigolin GM; Levato L; Giordano A; Del Poeta G; Stelitano C; Deodato M; Ielo C; Noto A; Guarente V; Coscia M; Tedeschi A; Gaidano G; Cuneo A; Foa' R; Trentin L; Mauro FR
    Am J Hematol; 2022 May; 97(5):E176-E180. PubMed ID: 35170793
    [No Abstract]   [Full Text] [Related]  

  • 16. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
    Coppola PE; Broccoli A; Argnani L; Casadei B; Stefoni V; Bertuzzi C; Sabattini E; Zinzani PL
    Leuk Lymphoma; 2021 Dec; 62(14):3540-3543. PubMed ID: 34348068
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 20. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.